Hepatitis C News

WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.

Wanted: a prominent scientist to lead a $6.3 billion research organization.

When I was in high school, I had an opportunity to shadow the medical field through the Girl Scouts. This led to me volunteering at a hospital during undergrad.

WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.

WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.

WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.

WASHINGTON — An expert panel of physicians, researchers and scientific advisers called upon The Liver Meeting attendees to support a proposed national HCV elimination program in the US.

WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.

WASHINGTON — Patients with alcohol use disorder and diabetes mellitus or hepatitis C were at higher risk for advanced liver disease, while African American race had a protective effect, according to late-breaking data at The Liver Meeting.

People with hepatitis C, either treated or untreated, had an increased risk for developing active tuberculosis, according to data published in Clinical Infectious Diseases.